Key result
IRES sequence variability shows no association with interferon efficacy.
Why the study?
The significance of genetic variations in the HCV internal ribosome entry site (IRES) on interferon therapy efficacy and serum HCV-RNA levels in clinical settings is not fully known.
Do nucleotide sequence variations in the internal ribosome entry site of HCV-1b influence interferon efficacy or serum HCV-RNA levels in patients with chronic HCV-1b infection?
Population
25 patients with chronic HCV-1b infection treated with interferon
Comparison
Sustained responders vs nonresponders to interferon therapy
Design
Observational cohort study with PCR and sequencing of IRES
Follow-up
6 months after the end of interferon treatment
Authors
Loading...
IRES variants in HCV may affect translation; leaves open their clinical impact on infection outcomes.
Observational (n=25)
Do nucleotide sequence variations in the internal ribosome entry site of HCV-1b influence interferon efficacy or serum HCV-RNA levels in patients with chronic HCV-1b infection?
Absolute Event Rate: 1.8% vs 2.1%
p-value: p=.30
Sequence variability of the internal ribosome entry site has no influence on interferon efficacy or serum HCV-RNA concentrations in patients with chronic HCV-1b infection.
Yamamoto et al. (1997) conducted an observational in HCV-1b infection (n=25). IRES sequence variability was evaluated on Number of nucleotide substitutions in the IRES (p=.30). IRES sequence variability had no significant association with interferon efficacy, with a mean of 1.8 nucleotide substitutions in sustained responders versus 2.1 in nonresponders (P=0.30).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: